<DOC>
	<DOCNO>NCT02555839</DOCNO>
	<brief_summary>There high unmet medical need anti-myeloma therapy RRMM patient previously treat Lenalidomide Bortezomib , due poor prognosis . This observational study focus collection data concern safe optimal usage Pomalidomide , new therapy option RRMM patient , thereby increase knowledge optimal AE management . Beside , analysis tolerability , dosage efficacy perform . This knowledge could lead optimization Pomalidomide usage treatment .</brief_summary>
	<brief_title>Treatment Relapsed/Refractory Multiple Myeloma ( rrMM ) With Pomalidomide Clinical Practice</brief_title>
	<detailed_description>There high unmet medical need anti-myeloma therapy patient RRMM previously treat Lenalidomide Bortezomib contain regimen active tolerable , patient poor prognosis . Hands-on experience Pomalidomide limit Austria non-interventional study enhances attention pay safe use handle product well increase knowledge optimal adverse event ( AE ) management substantially . A detailed record medical history include . co-morbidities pre-treatment regimen allow analysis impact tolerability , dosage efficacy . Beside collection data efficacy tolerability observational drug utilization study could give insight clinical practice routine use Pomalidomide .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Age &gt; 18 year 3 . Relapsed/refractory MM 4 . â‰¥2 antimyeloma treatment ( Lenalidomide Bortezomib ) 5 . Refractory last pretreatment 6 . Adequate contraception accord monitoring plan 7 . Adequate thrombosis prophylaxis 1 . Pregnant Lactating Females 2 . Known hypersensitivity Imnovid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Imnovid</keyword>
	<keyword>Non-interventional</keyword>
</DOC>